People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Unum Therapeutics Inc. | — | Biotechnology | Series D+ | $220.5M | $4.3B | 2020 |
Karen L. Ferrante at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karen L. Ferrante on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Booth | 1 | 12 |
| Ben Auspitz | 1 | 9 |
| Charles Wilson | 1 | 5 |
| Liam Ratcliffe | 1 | 4 |
| Arlene L. Morris | 1 | 1 |
| Jessica L. Sachs | 1 | 1 |
| Chris L. Cain | 1 | 1 |
| Peter L. Harwin | 1 | 1 |
| Christiana Stamoulis | 1 | 1 |
| Matthew L. Ros | 1 | 1 |
| John L. Green | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.